John Burt

Biography

John Burt was appointed Chief Executive Officer in May 2011. John has been leading the group to deliver its international growth strategy to enable the development of better biopharmaceuticals through organic growth, technology innovation and acquisitions. John has led the delivery of the M&A strategy that has brought together the businesses of PolyTherics, Antitope, PacificGMP and TCRS into the Abzena group, and the transition to AIM-quoted business on the London Stock Exchange in July 2014. Previously, John co-founded Thiakis with Professor Sir Steve Bloom (Imperial College), and he served as Chief Executive Officer through to its successful acquisition by Wyeth Pharmaceuticals in December 2008. Earlier in his career John held a range of roles covering finance, technology licensing and business and corporate development roles with Vanguard Medica plc (now part of Vernalis plc), GlaxoWellcome / GlaxoSmithKline and Imperial Innovations. John was awarded a DPhil (molecular biology) from University of Oxford, following his first degree in Natural Sciences at the University of Cambridge.

Research Interest

biopharmaceuticals